Haglund C, Huhtala M L, Halila H, Nordling S, Roberts P J, Scheinin T M, Stenman U H
Br J Cancer. 1986 Aug;54(2):297-303. doi: 10.1038/bjc.1986.176.
The serum and urine concentrations of a tumour-associated trypsin inhibitor, TATI, were determined by radioimmunoassay in patients with pancreatic cancer and with benign pancreatic and biliary diseases. Elevated serum levels (greater than 20 micrograms l-1) were found in 85% of the patients with pancreatic cancer, and elevated urine levels (greater than 50 micrograms g-1 creatinine) in 96% of the patients. Thus low TATI level, especially in urine, makes the possibility of pancreatic cancer less likely. Serial assay of TATI in serum from three patients with surgically removed pancreatic cancer showed elevation of the TATI level at the time of detection of recurrence. However, high serum and urine levels were also seen in pancreatitis and in benign extrahepatic cholestasis. Thus TATI is a sensitive, although not specific, indicator of pancreatic and biliary disease, but the use of TATI as a tumour marker in the primary diagnosis of pancreatic cancer is limited. Immunohistochemical staining of pancreatic lesions showed that half of the pancreatic tumours expressed TATI, but the pancreatic tissue adjacent to a carcinoma always stained stronger than the carcinoma. It therefore seems that the main source of TATI in serum and urine of patients with pancreatic cancer are the normal acini and not the tumour tissue. In pancreatitis the staining was intense and clearly stronger than in normal pancreas.
采用放射免疫分析法测定了胰腺癌患者以及胰腺和胆道良性疾病患者血清和尿液中一种肿瘤相关胰蛋白酶抑制剂（TATI）的浓度。85%的胰腺癌患者血清水平升高（大于20微克/升），96%的患者尿液水平升高（大于50微克/克肌酐）。因此，TATI水平低，尤其是尿液中的低水平，使患胰腺癌的可能性降低。对3例手术切除胰腺癌患者的血清进行TATI连续检测，结果显示复发检测时TATI水平升高。然而，胰腺炎和良性肝外胆汁淤积患者也可见血清和尿液高水平。因此，TATI是胰腺和胆道疾病的一个敏感指标，尽管并非特异性指标，但TATI作为胰腺癌初步诊断的肿瘤标志物其应用有限。胰腺病变的免疫组织化学染色显示，一半的胰腺肿瘤表达TATI，但癌旁胰腺组织的染色总是比癌组织更强。因此，胰腺癌患者血清和尿液中TATI的主要来源似乎是正常腺泡而非肿瘤组织。在胰腺炎中，染色强烈且明显强于正常胰腺。
